옵션 체인은 다양한 행사가격과 만기일에 대한 Genprex의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Genprex에 대한 시장 심리를 평가합니다..

Genprex (NASDAQ:GNPX) 주식, 옵션 체인

Genprex

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Exclusives

Trading Ideas

AAPL

AMZN

DRUG

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 10월에 벤징가 프로에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 실적은 11월 1일 기준이며 배당금은 포함되지 않았다.

독점: 벤징가 프로에서 10월 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, DJT 순위는?

Genprex Inc

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) with a Buy and maintains $20 price target.

News

Price Target

Analyst Ratings

SONN

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $20 Price Target

Benchmark analyst Cody Acree reiterates Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) with a Buy and maintains $60 price target.

Reiteration

TSEM

Benchmark Reiterates Buy on Tower Semiconductor, Maintains $60 Price Target

MasterCraft Boat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCFT#NASDAQ">MCFT</a>) (the "Company"), today announced that Tim Oxley, Chief Financial Officer, has decided to retire from the Company, effective December 31, 2025. Scott Kent, Vice President of Finance, will succeed Mr. Oxley as Chief Financial Officer, effective July 1, 2025. Mr. Oxley will transition to serve as a special advisor to the executive team/Board from July 1, 2025 until December 31, 2025, to ensure a smooth transition of responsibilities.
Mr. Kent has 33 years of professional experience, including 28 years of direct marine industry experience and is the ideal successor for the CFO role. He has served as Vice President of Finance for MasterCraft since 2018, leading the finance function, including accounting, FP&amp;A, financial reporting, and treasury. Throughout his tenure, he has also helped lead operational and strategic advancements across the business. Prior to joining MasterCraft, Mr. Kent served as Chief Financial Officer at Brunswick Boat Group and Recreational Boat Group, as well as various positions of increasing responsibility at Brunswick, Sea Ray Boats, and Price Waterhouse. Mr. Kent has a bachelor's of science in Accounting from the Milligan College and has held license as a CPA.

Management

MCFT

MasterCraft Names Scott Kent as New CFO, Succeeding Retiring Finance Chief Tim Oxley

General

AMBC

Ambac Financial Group Provides Update On Sale Of Ambac Assurance Corporation; Says Term Of Purchase Agreement Extended From Apr. 4 To Jul. 3

TEVA

Teva Announces FDA Filing Acceptance For AJOVY In Pediatric Episodic Migraine Prevention

Zelle's standalone mobile app officially shut down on April 1, leaving some users wondering how they can keep sending money digitally. 
What Happened: Launched in 2017, Zelle quickly gained popularity by partnering with major financial institutions nationwide. Today, more than 2,200 U.S. banks and credit unions support Zelle, driving usage of the separate app below 2%— making its closure unsurprising.
As noted by CNET in a <a href="https://www.cnet.com/personal-finance/banking/the-zelle-app-has-shut-down-heres-how-you-can-still-send-money-digitally/">report</a>, Zelle itself isn't going anywhere. You can still transfer funds through your bank's app or website if it participates in the Zelle network, which includes Bank of America, Chase, Wells Fargo, TD Bank, PNC Bank and Citi. If you'd rather switch, Apple Wallet, Cash App, PayPal and Venmo remain prominent alternatives for electronic transactions.
See also: <a href="https://www.benzinga.com/25/04/44662249/end-of-cheap-clothing-era-tariffs-to-hit-apparel-industry-hard">Tariffs Threaten To End Era Of Cheap Clothing — Apparel Industry Faces Major Price Shock Under Trump Policy</a>
Why It Matters: The shutdown follows <a href="https://www.benzinga.com/news/legal/24/12/42687945/zelle-became-a-gold-mine-for-fraudsters-consumer-financial-protection-bureau-lawsuit">scrutiny Zelle faced</a> last year, when the Consumer Financial Protection Bureau sued it and three major U.S. banks over allegations of rampant fraud on the peer-to-peer payment network. That <a href="https://in.benzinga.com/news/legal/25/03/44122330/cfpb-drops-zelle-fraud-reimbursement-case-against-jpmorgan-wells-fargo">lawsuit was dropped</a>, but concerns about digital security linger. Zelle, for its part, says it's prioritizing its bank partnerships because "the vast majority of people" already access the service through their financial institution.
Regardless of the platform you use, experts warn against sending money to unfamiliar recipients. Chase recently blocked certain Zelle transactions it considered suspicious, bringing to light broader worries about scams. 
Remain vigilant for urgent messages or offers that appear too good to be true — common signs of fraud. Stay informed, trust your instincts, and choose a service that combines convenience with solid safety measures. Even without the standalone Zelle app, you can still move money swiftly while taking steps to protect yourself.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/25/04/44662021/is-tesla-cybertruck-the-biggest-automotive-blunder-in-decades-after-fords-edsel-its-a-huge-swing-and-a-huge-miss">Is Tesla Cybertruck The Biggest Automotive Blunder In Decades After Ford&#8217;s Edsel? &#8216;It&#8217;s A Huge Swing And A Huge Miss,&#8217; Says Expert</a>

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

Zelle Ends Standalone App But Banks Still Let You Pay Through The Network: Here's How

Telsey Advisory Group analyst Cristina Fernandez maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Outperform and maintains $280 price target.

Telsey Advisory Group Maintains Outperform on RH, Maintains $280 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) with a Market Perform and maintains $2.5 price target.

COOK

Telsey Advisory Group Maintains Market Perform on Traeger, Maintains $2.5 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor initiates coverage on Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy rating and announces Price Target of $45.

Initiation

IONS

HC Wainwright & Co. Initiates Coverage On Ionis Pharmaceuticals with Buy Rating, Announces Price Target of $45

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $46 price target.

AVXL

D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

Needham analyst Mike Cikos reiterates DigitalOcean Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) from Hold to Hold.

DOCN

Needham Reiterates Hold on DigitalOcean Holdingsto Hold

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

OSTX

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

HC Wainwright &amp; Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) with a Buy and lowers the price target from $45 to $44.

BCAX

HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $44

Magnificent 7 stocks, which are the heavyweights in the benchmark indices of the U.S. stock market, declined in premarket on Monday, extending the fall from the tariff-induced selloff last week.
What Happened: Shares of Elon Musk&#8216;s Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Mark Zuckerberg&#8216;s Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) dropped the most by 5.19%% and 2.47%, respectively, as of the publication of this article.
The other components of the Magnificent 7 were all down over 1%. Tesla and Jensen Huang&#8216;s Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) have had the steepest fall on a year-to-date basis in 2025.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks</td>
<td>Monday Premarket</td>
<td>YTD Performance</td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>-3.34%</td>
<td>-31.81%</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>-2.96%</td>
<td>-22.75%</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>-1.43%</td>
<td>-14.03%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>-2.51%</td>
<td>-22.35%</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</td>
<td>-2.05%</td>
<td>-22.50%</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>-2.47%</td>
<td>-15.77%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>-5.19%</td>
<td>-36.87%</td>
</tr>
</tbody>
</table>
</figure>
The market has been witnessing a staggering crash since Thursday, after President Donald Trump unveiled tariffs on U.S. trading partners on Wednesday after the close. Top analysts and economists have issued recession warnings following the introduction of these policy changes.
Goldman Sachs increased its recession probability forecast to <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy?">45% from 35%</a> on Sunday, following a prior hike a month ago, attributing the increased risk to tighter financial conditions and higher policy uncertainty, a view shared by JPMorgan, which raised its global <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy?_gl=1&#x2A;1mnei8t&#x2A;_gcl_au&#x2A;NzQyMjgxNjUuMTczNzYwNzI4NQ..&#x2A;_ga&#x2A;ZGVsZXRlZA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NDAyMzE1Ny4yNDYuMS4xNzQ0MDIzMjMyLjAuMC4w">recession odds to 60%</a> last week. However, Jefferies analysts suggest these factors, including Trump&#8217;s tariffs, could offer tech companies a &#8220;Free Hall Pass&#8221; to revise their financial guidance
As reported <a href="https://markets.businessinsider.com/news/stocks/tariffs-free-hall-pass-to-reset-big-tech-profit-guidance-2025-4">by</a> Business Insider, the firm&#8217;s lead analyst, Brent Thill, suggests companies can leverage this crisis to set lower, more attainable estimates, potentially boosting investor sentiment and stock performance. 
See Also: <a href="https://www.benzinga.com/25/04/44662164/us-stock-futures-slump-following-massive-tariff-induced-selloff-experts-warn-of-a-brewing-great-depression-like-pattern">US Stock Futures Slump Following Massive Tariff-Induced Selloff: Experts Warn Of A Brewing &#8216;Great Depression-Like&#8217; Pattern</a>
Why It Matters: The movement in these seven stocks has a huge impact on the overall market as they comprise nearly 32% of the S&amp;P 500&#8217;s weight.
As of Friday, the S&amp;P 500 was nearing the bear market zone as it closed 17.46% lower than its previous record high of 6,147.43 points.
Dow was 14.99% down from its 52-week high of 45,073.63 points, whereas the Nasdaq 100 was already in the bear market territory, 21.71% lower from its high of 22,222.61 points.
The hopes of a <a href="https://www.benzinga.com/25/04/44661029/trump-and-fed-stand-firm-lack-of-a-put-could-drive-the-market-lower-very-quickly-warns-expert">Fed &#8216;put&#8217; remained on standby</a> as Jerome Powell said Friday that "It is too soon to say what will be the appropriate path for monetary policy.&#8221;
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined in premarket on Monday. The SPY was down 2.10% to $494.66, while the QQQ declined 2.24% to $413.21, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44662730/bill-ackman-slams-commerce-secretary-lutnick-for-ignoring-stock-market-crash-he-and-cantor-are-long-bonds">Bill Ackman Slams Commerce Secretary Howard Lutnick For Ignoring Stock Market Crash: &#8216;He And Cantor Are Long Bonds&#8217;</a></li>
</ul>
Image via Shutterstock

Equities

Markets

GOOG

Tesla, Nvidia, Apple And Other 'Magnificent 7' Peers Tank In Monday Premarket: What's Going On?

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $42 price target.

HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $42 Price Target

Together, Domino's and WorkInProgress have navigated a post-pandemic world, helping Domino's face economic and categorical headwinds to maintain its No. 1 position

Domino's Extends WorkInProgress Partnership Through 2027; Celebrates Breakthrough Campaigns, No. 1 Pizza Brand Status

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Instacart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>)</h3>
<ul>
<li>On April 3, Wells Fargo analyst Ken Gawrelski maintained Maplebear with an Equal-Weight rating and lowered the price target from $47 to $44. The company's stock fell around 6% over the past month and has a 52-week low of $29.84.</li>
<li>RSI Value:30</li>
<li>CART Price Action: Shares of Instacart fell 6.6% to close at $37.37 on Friday.</li>
<li>Edge Stock Ratings: 73.72 Momentum score with Value at 57.23. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/cart"><img loading="lazy" decoding="async" width="440" height="168" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071358/image-57.png" alt="" class="wp-image-859673" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071358/image-57.png 440w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071358/image-57-300x115.png 300w" sizes="(max-width: 440px) 100vw, 440px" /></a></figure>
<h3 class="wp-block-heading">Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On March 20, Stifel analyst Mark Astrachan maintained Walmart with a Hold and lowered the price target from $99 to $93. The company's stock fell around 9% over the past month and <a href="https://www.benzinga.com/quote/WMT">has a 52-week low</a> of $58.56.</li>
<li>RSI Value: 29.5</li>
<li>WMT Price Action: Shares of Walmart dipped 4.7% to close at $83.19 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407">trend in WMT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407"><img loading="lazy" decoding="async" width="917" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071504/image-58.png" alt="" class="wp-image-859674" style="width:535px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071504/image-58.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071504/image-58-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071504/image-58-768x701.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Archer-Daniels-Midland Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>)</h3>
<ul>
<li>On March 27, ADM And Mitsubishi signed a memorandum of understanding to explore potential areas of collaboration across agriculture supply chain. The company's stock fell around 12% over the past month and has a 52-week<a href="https://www.benzinga.com/quote/ADM"> low of $43.01</a>.</li>
<li>RSI Value: 22.4</li>
<li>ADM Price Action: Shares of Archer-Daniels-Midland fell 8.9% to close at $43.32 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407">ADM shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407"><img loading="lazy" decoding="async" width="798" height="737" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071553/image-59.png" alt="" class="wp-image-859676" style="width:462px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071553/image-59.png 798w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071553/image-59-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071553/image-59-768x709.png 768w" sizes="(max-width: 798px) 100vw, 798px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a> </li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>.
Photo via Shutterstock

Dividends

Pre-Market Outlook

CART

Top 3 Defensive Stocks That Are Preparing To Pump This Month

CureVac N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvac#NASDAQ">CVAC</a>) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the U.S. Food and Drug Administration
CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 clinical study of CVHNLC in patients with squamous non-small cell lung cancer (sqNSCLC). CVHNLC is CureVac's investigational mRNA-based precision immunotherapy consisting of two different mRNA constructs encoding eight tumor-associated antigens (TAAs) with prevalence across sqNSCLC patients. Encoded antigens include a novel class of TAAs that have not been previously tested in cancer immunotherapy trials.
The phase 1, dose-finding, open-label study will assess the safety and tolerability of CVHNLC plus pembrolizumab in patients with advanced sqNSCLC. The study comprises a dose-escalation part (Part A) of first-line maintenance treatment after either chemotherapy combined with pembrolizumab or pembrolizumab monotherapy. This is followed by an optional dose expansion part (Part B) in which CVHNLC is tested in combination with first-line chemotherapy and pembrolizumab.

Government

Penny Stocks

Regulations

Small Cap

CVAC

CureVac Gets FDA Green Light for Lung Cancer Trial With mRNA-Based Immunotherapy

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower on continued weakness following President Trump's recent tariff announcements, which have caused global trade war concerns.

Wallbox Celebrates 100K EV Chargers Made In Arlington; Commits To Long-Term U.S. Electrification Push

Press Releases

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Contracts

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex to Participate at BIO Europe Spring 2025

CS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fasttrack – GNPX, BON, SES, BETRF – Stocks to Watch Now!

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

BETRF

CSDX

CSE:BETR

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Ensysce Biosciences

Entero Therapeutics

Galecto

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Organovo Holdings

Palisade Bio

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Synaptogenix

Tharimmune

Theriva Biologics

Longevity Health Holdings, Inc. - Common Stock

Comments

Genprex

Genprex (GNPX) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌